急性冠状动脉综合征患者早期辛伐他汀干预对血脂和高敏C反应蛋白的影响
急性冠状动脉综合征,,急性冠状动脉综合征；C反应蛋白；血脂；辛伐他汀,1资料与方法,2结果,3讨论,参考文献
【摘要】 目的 观察急性冠状动脉综合征(ACS)患者早期辛伐他汀治疗对血清高敏C反应蛋白(hsCRP)和血脂水平的影响，探讨他汀类药物在ACS早期干预中的作用。方法 选择住院的ACS患者80例，采用随机、单盲、对照方法将ACS患者分为对照组(n=38,每日口服安慰剂)和辛伐他汀治疗组(n=42, 辛伐他汀20 mg/d，发病48 h内开始服用)，两组其他治疗相同；观察4周，于治疗前后分别检测患者血清hs-CRP及血脂的浓度。hsCRP浓度采用酶联免疫吸附法测定,血脂采用酶法。结果 治疗4周后，辛伐他汀组与对照组相比，患者血清hsCRP和总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDLC)浓度显著降低(P均<001)，而对照组治疗前后差异无显著性(均为P>005)。结论 ACS患者早期辛伐他汀治疗可明显改善血脂，降低hsCRP水平。辛伐他汀具有减少炎症反应和稳定斑块的作用。【关键词】 急性冠状动脉综合征；C反应蛋白；血脂；辛伐他汀
【中图分类号】 R541
Therapeutic effect of simvastatin on serum lipids and high sensitive Creactive protein
in patients with acute coronary syndrome at the early stage
LI Zhi ZHANG Juan DING Guofeng
Department of Lemology,Binzhou Medical College, Binzhou 256603
【Abstract】 Objective to observe the effect of simvastatin on serum lipids and high sensitive Creactive protein(hsCRP) at the early stage in patients with acute coronary syndrome (ACS).Methods 80 hospitalized patients with ACS were selected and were randomly divided into control group(with placebo for 4 weeks, n=38) and simvastatin group(with simvastatin 20mg per day,n=42). Simvastatin and placebo were used within 48 hours from onset,and there were no other different therapeutic methods between two groups. The concentrations of serum lipids and hsCRP were detected before and after 4 weeks treatment by ELISA and enzymatic cholesterol assay.Results In simvastatin group, levels of serum total cholesterol(TC),triglycerides(TG), lower density lipid cholesterol(LDLC) and hsCRP decreased significantly compared with those before treatment (P<001) ,but there was no significant change in control group(P>005), Conclusion Simvastatin can lower levels of serum lipids and hsCRP in patients with acute coronary syndrome at the early stage, therefore simvastatin has antiinflammatory therapeutic effect and may stabilize atherosclerotic plaques. ......
您现在查看是摘要页，全文长 9438 字符。